Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Taiho Oncology, Inc. (Sponsor)
CONTACT
Lead
Taiho Oncology, Inc.
This is an open-label EAP treatment protocol of zipalertinib for the treatment of patients with advanced NSCLC with EGFR ex20ins mutations who have exhausted standard treatment options, are new to therapy with zipalertinib, and for whom therapy with zipalertinib is clinically indicated. Patients will be enrolled through the MyAccess Programs Platform.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted